Metabolic stability of human parathyroid hormone peptide hPTH (1-34) in rat tissue homogenates: Kinetics and products of proteolytic degradation

Amino Acids

Volumn 38, Issue 5, 2010, Pages 1595-1605

  Liao, Sha ^a   Qie, Jian Kun ^a   Xue, Ming ^a,b   Zhang, Zhen Qing ^a   Liu, Ke Liang ^a   Ruan, Jin Xiu ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cleavage site; Degradation; Enzyme inhibitors; Human parathyroid hormone; Mass spectrometry

Indexed keywords

1,10 PHENANTHROLINE; APROTININ; ASPARAGINE; DYFLOS; EDETIC ACID; LEUCINE; METALLOPROTEINASE INHIBITOR; PARATHYROID HORMONE[1-34]; PROTEINASE; SERINE PROTEINASE INHIBITOR; PARATHYROID HORMONE;

AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ARTICLE; CALCIUM HOMEOSTASIS; CARBOXY TERMINAL SEQUENCE; CHEMICAL BOND; CIRCULAR DICHROISM; CONTROLLED STUDY; DEGRADATION KINETICS; DRUG DEGRADATION; DRUG HALF LIFE; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME INHIBITION; IN VITRO STUDY; LIVER METABOLISM; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLIC INHIBITION; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE HOMOGENATE; TISSUE SPECIFICITY; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; HUMAN; HYDROLYSIS; KINETICS; MASS SPECTROMETRY; METABOLISM; MOLECULAR GENETICS; SPRAGUE DAWLEY RAT;

RATTUS;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; HYDROLYSIS; KINETICS; MALE; MOLECULAR SEQUENCE DATA; PARATHYROID HORMONE; RATS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 77955901683     PISSN: 09394451     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00726-009-0376-y     Document Type: Article

References (25)

1. Boulanger L, Roughly P, Gaudreau P (1992) Catabolism of rat growth hormone-releasing factor (1-29) amide in rat serum and liver. Peptides 13:681-689
2. Chu NN, Li XN, Chen WL, Xu HR (2007) Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers. Pharmazie 62:869-871 (Pubitemid 350144623)
3. Daugaard H, Egfjord M, Lewin E, Olgaard K (1994a) Metabolism of N-terminal and C-terminal parathyroid hormone fragments by isolated perfused rat kidney and liver. Endocrinology 134:1373-1381 (Pubitemid 24085593)
4. Daugaard H, Egfjord M, Lewin E, Olgaard K (1994b) Metabolism of intact PTH by isolated perfused kidney and liver from uremic rats. Exp Nephrol 2:240-248 (Pubitemid 24201690)
5. Ekins S, Ring BJ, Grace J, McRobie-Belle DJ, Wrighton SA (2000) Present and future in vitro approaches for drug metabolism. Pharmacol Toxicol Methods 44:313-324 (Pubitemid 32239483)
6. Flamini R, De Rosso M (2006) Mass spectrometry in the analysis of grape and wine proteins. Expert Rev Proteom 3:321-331 (Pubitemid 43979406)
7. Föger F, Kopf A, Loretz B, Albrecht K, Bernkop-Schnürch A (2008) Correlation of in vitro and in vivo models for the oral absorption of peptide drugs. Amino Acids 35:233-241 (Pubitemid 351799196)
8. Fraenkel L, Gulanski B, Wittink D (2007) Patient willingness to take teriparatide. Patient Educ Couns 65:237-244 (Pubitemid 46073565)
9. Galluppi GR, Rogge MC, Roskos LK, Lesko LJ, MD Green, Feigal DW Jr (2001) Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report. Clin Pharmacol Ther 69:387-399 (Pubitemid 32564927)
10. Hamdy R (2002) Osteoporosis, the deafening silent epidemic. South Med J 95:567-568 (Pubitemid 34651540)
11. Hu Z, Niu H, Yang X, Li H, Sang G, Li B (2006) Recombinant human parathyroid hormone 1-34: pharmacokinetics, tissue distribution and excretion in rats. Int J Pharm 317:144-154
12. John H, Walden M, Schäfer S, Genz S, Forssmann WG (2004) Analytical procedures for quantification of peptides in pharmaceutical research by liquid chromatography-mass spectrometry. Anal Bioanal Chem 378:883-897 (Pubitemid 40890201)
13. Jones KO, Owusu-Ababio G, Vick AM, Khan MA (2006) Pharmacokinetics and hepatic extraction of recombinant human parathyroid hormone, hPTH (1-34), in rat, dog, and monkey. J Pharm Sci 95:2499-2506 (Pubitemid 44726389)
14. Liao S, Zhang ZQ, Ruan JX, Qi JK, Liu KL (2008) Degradation of salmon calcitonin in rat kidney and liver homogenates. Pharmazie 63:743-747
15. Neuman WF, Neuman MW, Sammon PJ, Simon W, Lane K (1975) The metabolism of labeled parathyroid hormone. III. Studies in rats. Calcif Tissue Res 18:251-261
16. Pezeshki A, Vergote V, Van Dorpe S, Baert B, Burvenich C, Popkov A, De Spiegeleer B (2009) Adsorption of peptides at the sample drying step: influence of solvent evaporation technique, vial material and solution additive. J Pharm Biomed Anal 49:607-612
17. Potetinova Z, Barbier JR, Suen T, Dean T, Gardella TJ, Willick GE (2006) C-terminal analogues of parathyroid hormone: effect of C-terminus function on helical structure, stability, and bioactivity. Biochemistry 45:11113-11121 (Pubitemid 44413658)
18. Powell MF, Grey H, Gaeta F, Sette A, Colon S (1992) Peptide stability in drug development: a comparison of peptide reactivity in different biological media. J Pharm Sci 81:731-735 (Pubitemid 23006807)
19. Quattrocchi E, Kourlas H (2006) Teriparatide: a review. Clin Ther 26:841-854 (Pubitemid 38943033)
20. Reeve J (2002) Recombinant human parathyroid hormone. BMJ 324:435-436 (Pubitemid 34169453)
21. Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson- Hughes B, Jönsson B, Pols H, Cramer JA (2007) Noncompliance: the Achilles' heel of anti-fracture therapy. Osteoporos Int 18:711-719 (Pubitemid 46684777)
22. Tomás R, Klepárník K, Foret F (2008) Multidimensional liquid phase separations for mass spectrometry. J Sep Sci 31:1964-1979 (Pubitemid 352003181)
23. Van den Broek I, Sparidans RW, Schellens JH, Beijnen JH (2008) Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. J Chromatogr B 872:1-22
24. Vergote V, Van Dorpe S, Peremans K, Burvenich C, De Spiegeleer B (2008) In vitro metabolic stability of obestatin: kinetics and identification of cleavage products. Peptides 29:1740-1748
25. Werle M, Bernkop-Schnurch A (2006) Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30:351-367 (Pubitemid 43886897)